期刊文献+

机械瓣膜置换术后华法林与细胞色素P4502C9和维生素K环氧化物还原酶亚单位1基因多态性的相关性研究 被引量:5

原文传递
导出
摘要 机械瓣膜置换术患者需终生服用华法林抗凝治疗,华法林通过竞争性结合维生素K环氧化物还原酶亚单位1(VKORC1)阻断维生素K依赖性凝血因子生成达到抗凝效果,体内华法林通过肝细胞微粒体中药酶细胞色素P450酶即CYP2C9代谢。我们采用聚合酶链式反应-限制性片段长度多态性技术(PCR-RFLP),探讨华法林维持剂量与VKORC1启动子区1639-A/G(VKORC1-1639A/G)和CYP2C9基因多态的相关性。
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2007年第10期1272-1272,共1页 Chinese Journal of Experimental Surgery
基金 新疆维吾尔自治区科技攻关和重点科技项目(200233118)
  • 相关文献

参考文献2

  • 1Elizabeth A, Sconce Tayyaba I, Khan Hilary A, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen. Blood,2005,106:2329-2333.
  • 2王志伟,徐明星,计乐群.心脏瓣膜置换术后低强度抗凝研究[J].中华实验外科杂志,2005,22(4):484-485. 被引量:21

二级参考文献7

  • 1Katircioglu SF, Yamak B, Ulus AT, et al. Mitral valve replacement with St. Jude medical prosthesis and low dose anticoagulation in patients aged over 50 years. J Heart Valve Dis, 1998, 7:455-458.
  • 2Kanalka Y, Tanemoto K, Murakami T, et al. Thromboembolic and bleeding complications in patients treated with oral anticoagulant therapy after mechanical heart valve prostheses implantation. Kyobu-Geka,2000, 53:754-757.
  • 3Rosendaal FR, Van der Meer FJM, Cannegicter SC. Management of anticoagulant therapy the dutch experience. J Thromb Thrombolysis,1996,2:265-269.
  • 4Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest,1992,102:445-455.
  • 5Hirsh J, Dalen JE, Deykin D, et al. mechanism of a clinical effectiveness and optimal therapeutic range of Oral anticoagulants. Chest, 1992, 102:312-314.
  • 6Horstkotte D, Schulte H, Bircks W, et al. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude medical prostheses. J Heart Valve Dis, 1993, 2: 291-293.
  • 7杜心灵,张凯伦,胡志伟,蓝鸿钧,金咏梅.人工机械瓣膜替换术后凝血功能改变及合理抗凝强度的研究[J].中华实验外科杂志,1999,16(1):62-63. 被引量:16

共引文献20

同被引文献60

  • 1孟旭,李金钟,刘岩,张海波.人工机械瓣膜置换术后口服抗凝药的抗凝治疗强度标准[J].中华心血管病杂志,2004,32(7):618-621. 被引量:58
  • 2王志伟,徐明星,计乐群.心脏瓣膜置换术后低强度抗凝研究[J].中华实验外科杂志,2005,22(4):484-485. 被引量:21
  • 3蒋年新,宋杰,徐标.维生素K环氧化物还原酶复合体1基因多态性对华法林维持剂量的影响[J].中华心血管病杂志,2007,35(7):652-654. 被引量:5
  • 4Wadelius M,Pirmohamed M.Pharmacogenetics of warfarin:cur-rent status and future challenges.Pharmacogenomics J,2007,7:99-111.
  • 5Veenstra DL,You JH,Rieder MJ,et al.Association of VitaminK epoxide reductase complex 1(VKORC1)variants with warfa-rin dose in a Hong Kong Chinese patient population.Pharmaco-genet Genomics,2005,15:687-691.
  • 6Lindh JD,Holm L,Andersson ML,et al.Influence of CYP2C9genotype on warfarin dose requirements-a systematic review andMeta-analysis.Eur J Clin Pharmacol,2009,65:365-372.
  • 7Miao L,Yang J,Huang C,et al.Contribution of age,bodyweight,and CYP2C9 and VKORC1 genotype to the anticoagulantresponse to warfarin:proposal for a new dosing regimen in Chinesepatients.Eur J Clin Pharmacol,2007,63:1135-1142.
  • 8Lee MT,Chen CH,Chou CH,et al.Genetic determinants of war-farin dosing in the Han-Chinese population.Pharmacogenomics,2009,10:1905-1919.
  • 9黄盛文,徐湘民.VKORC1和CYP2C9基因型对中国人华法林个体化用药剂量影响的前瞻性研究.南方医科大学,博士学位论文2008.
  • 10吴晓盈,程琼,陈慧.基因多态性对老年房颤患者华法林代谢和药效的影响.硕士学位论文,福建医科大学,2008.

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部